Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

Core Viewpoint - Curis, Inc. is set to report its second quarter 2025 financial and operational results on August 5, 2025, with a conference call scheduled for the same day [1]. Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3]. - Emavusertib is currently being evaluated in multiple clinical studies, including the TakeAim Lymphoma Phase 1/2 study for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and the TakeAim Leukemia Phase 1/2 study for patients with relapsed/refractory acute myeloid leukemia (AML) [3]. - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of PCNSL, AML, and myelodysplastic syndrome (MDS) [3]. - Curis holds exclusive licensing rights to emavusertib through a collaboration with Aurigene established in 2015 [3]. - The company has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3].